TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.

Paul A Meyers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.